Cancer Research Cancer Epigenetics  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 8486, September 15, 2007. doi: 10.1158/0008-5472.CAN-07-0498
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, F.
Right arrow Articles by Cusack, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, F.
Right arrow Articles by Cusack, J. C.

Molecular Biology, Pathobiology, and Genetics

Membrane-Bound Heparin-Binding Epidermal Growth Factor–Like Growth Factor Regulates E-Cadherin Expression in Pancreatic Carcinoma Cells

Fang Wang1, Callum Sloss1, Xiaobo Zhang2, Sam W. Lee3 and James C. Cusack1

1 Division of Surgical Oncology and 2 Gastrointestinal Unit and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts and 3 Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts

Requests for reprints: James C. Cusack, Division of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, 7th Floor, Yawkey Building, 55 Fruit Street, Boston, MA 02114. Phone: 617-724-4093; Fax: 617-724-3895; E-mail: jcusack{at}partners.org or Fang Wang, Division of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Jackson Building 904, 55 Fruit Street, Boston, MA 02114. Phone: 617-726-5165; Fax: 617-726-8623; E-mail: fwang6{at}partners.org.

Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a member of the EGF growth factor family. Initially synthesized as a membrane-bound precursor (pro-HB-EGF), it is cleaved at the juxtamembrane domain to release the soluble form of HB-EGF (s-HB-EGF) by sheddases, including matrix metalloproteinases (MMP) and a disintegrin and metalloproteinases. This is a process referred to as ectodomain shedding and is implicated in the process of all ligands of the EGF receptor (EGFR) family. The tumorigenic potential of s-HB-EGF has been studied extensively; however, the role of pro-HB-EGF in tumor progression is unknown, despite the fact that a considerable amount of pro-HB-EGF remains on the cell membrane. Our data here clearly indicated the distinct role of pro-HB-EGF in the regulation of E-cadherin expression and the epithelial-mesenchymal transition. We showed here that the expression of pro-HB-EGF was associated with the differentiation status in pancreatic tumors and cell lines. Expression of noncleaved pro-HB-EGF in pancreatic cells resulted in the up-regulation of E-cadherin through suppression of ZEB1, which is a transcriptional repressor of E-cadherin. Inhibition of HB-EGF shedding using a MMP inhibitor, GM6001, also dramatically augmented the E-cadherin expression while suppressing the EGFR activation. Moreover, up-regulation of E-cadherin by pro-HB-EGF not only resulted in cellular morphologic change but also decreased cell motility and enhanced apoptotic sensitivity in response to gemcitabine-erlotinib treatment. Collectively, our data defined a distinct role of pro-HB-EGF in the regulation of E-cadherin, suggesting that inhibition of shedding may be a novel approach to suppress pancreatic metastasis and sensitize cells to cancer therapy. [Cancer Res 2007;67(18):8486–93]




This article has been cited by other articles:


Home page
Hum ReprodHome page
B. Urman, B. Ata, K. Yakin, C. Alatas, S. Aksoy, R. Mercan, and B. Balaban
Luteal phase empirical low molecular weight heparin administration in patients with failed ICSI embryo transfer cycles: a randomized open-labeled pilot trial
Hum. Reprod., July 1, 2009; 24(7): 1640 - 1647.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Inuzuka, M. Tsuda, S. Tanaka, H. Kawaguchi, Y. Higashi, and Y. Ohba
Integral Role of Transcription Factor 8 in the Negative Regulation of Tumor Angiogenesis
Cancer Res., February 15, 2009; 69(4): 1678 - 1684.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Yagi, F. Yotsumoto, and S. Miyamoto
Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition
Mol. Cancer Ther., October 1, 2008; 7(10): 3441 - 3451.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.